URGN stock forecast, quote, news & analysis
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers... Show more
Why UroGen Pharma (URGN) Stock Is Up +11% in the Last 30 Days
Key Takeaways
- UroGen Pharma shares rose approximately 11% over the past 30 days, climbing from $36.80 on June 30 to $40.99 as of late July 2026.
- The FDA cleared an Investigational New Drug (IND) application for UGN-501, a next-generation oncolytic virus, enabling a Phase 1 trial in non-muscle invasive bladder cancer.
- The U.S. Patent and Trademark Office issued a Notice of Allowance for a key patent covering ZUSDURI and UGN-103 treatment methods, extending intellectual property protection into 2044.
- ZUSDURI's commercial launch continues to gain momentum following the permanent J-code implementation in January 2026, with Q1 revenue more than doubling quarter-over-quarter.
- Over the broader quarter, URGN surged roughly 72%, driven by strong Q1 financial results, positive clinical data, and multiple pipeline catalysts.
UroGen Pharma (URGN) Company Overview and Market Position
UroGen Pharma Ltd. is a commercial-stage biotechnology company focused on developing and commercializing innovative treatments for urothelial and specialty cancers. The company's proprietary RTGel® reverse-thermal hydrogel platform enables sustained-release drug delivery to the urinary tract, allowing for non-surgical tumor ablation. UroGen markets two FDA-approved products: JELMYTO® for low-grade upper tract urothelial cancer (LG-UTUC) and ZUSDURI™ (mitomycin) for intravesical solution, the first and only FDA-approved medicine for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). With a market capitalization of approximately $2 billion and trailing 12-month revenue of $140.5 million, UroGen has established a differentiated position in the niche urothelial cancer treatment market.
UroGen Pharma (URGN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 calendar days, URGN advanced from a closing price of $36.80 on June 30, 2026, to $40.99 on July 30, 2026, representing an increase of approximately 11.4%. The move pushed shares near their 52-week high and reflected sustained investor confidence following a series of positive regulatory and clinical announcements. The broader quarterly trend has been even more pronounced: URGN traded around $23.83 at the end of April 2026 and has since climbed roughly 72%, underscoring a powerful multi-month rally fueled by accelerating commercial execution and pipeline progress.
What Drove URGN Stock Price in the Last 30 Days
Several high-impact developments converged during the 30-day window. On July 8, UroGen announced that the FDA had cleared its IND application for UGN-501, a differentiated investigational next-generation oncolytic virus, with a Phase 1 clinical trial expected to begin enrolling patients in the fourth quarter of 2026. The program expands UroGen's pipeline beyond its RTGel-based mitomycin franchise and opens potential applications in other solid tumor settings. One week later, on July 15, the company disclosed a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering methods of treating recurrent LG-IR-NMIBC using ZUSDURI and UGN-103, supported by data from the ENVISION and ATLAS trials. Once issued, the patent extends protection to July 2044, significantly strengthening UroGen's intellectual property position. H.C. Wainwright reiterated a Buy rating and $45 price target on July 16, while Oppenheimer maintained an Outperform rating with a $40 target. Additionally, UroGen confirmed it will report second-quarter 2026 financial results on August 5, setting the stage for a potential catalyst event. The combination of pipeline expansion, patent certainty, and favorable analyst coverage drove the stock's double-digit percentage gain.
What Drove URGN Stock Performance Over the Last Quarter
The quarterly surge was rooted in accelerating commercial traction for ZUSDURI and a steady cadence of pipeline de-risking events. First-quarter 2026 results, reported on May 6, revealed total revenue of $51.0 million—up 152% year-over-year—with ZUSDURI contributing $29.2 million and more than doubling quarter-over-quarter. The permanent J-code, effective January 1, 2026, proved to be a critical reimbursement inflection point, with unique prescribers jumping from 102 to 256 in a single quarter. At the American Urological Association meeting in mid-May, UroGen presented three-year durability data showing a 64.5% probability of remaining event-free after achieving complete response with ZUSDURI. The company also announced that UGN-103 achieved a 94.5% six-month durability of response, with an NDA submission planned for the second half of 2026. In early June, UroGen reached a settlement with Teva Pharmaceuticals resolving JELMYTO patent litigation, securing approximately four years of protection against generic competition. The quarter's narrative of commercial execution, clinical validation, and regulatory progress fueled a sustained institutional re-rating of the stock.
Trending AI Robots
For traders seeking to complement fundamental analysis with technology-driven insights, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that actively trade thousands of tickers across different strategies and timeframes, but only the top-performing and most relevant bots earning the "Trending" designation appear in this section. The bots vary in strategy—from swing trading to trend following—and display transparent historical performance metrics, allowing users to evaluate each bot's track record. Whether monitoring stocks like URGN or scanning for opportunities across the broader market, this section provides a streamlined way to explore quantitative trading approaches powered by artificial intelligence.
URGN Stock Forecast Drivers: What Investors Should Watch Next
The immediate catalyst on the horizon is UroGen's second-quarter 2026 earnings report on August 5, which will provide updated ZUSDURI revenue figures, prescriber metrics, and any revisions to forward guidance. Beyond earnings, the planned NDA submission for UGN-103 in the second half of 2026 represents a major regulatory milestone, with potential FDA approval in 2027. Enrollment completion for the UGN-104 Phase 3 trial in LG-UTUC is expected by year-end, while the UGN-501 Phase 1 trial initiation in Q4 2026 will offer early signals on the oncolytic virus platform's viability. Macroeconomic factors including interest rate expectations and biotech sector fund flows may also influence URGN's trading range. Investors should monitor ZUSDURI's prescription trends, payer dynamics, and competitive developments within the uro-oncology landscape, while remaining aware of the company's ongoing net losses and cash burn rate as it continues investing in commercial infrastructure and pipeline development.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsURGN's Stochastic Oscillator dives oversold zone
The Stochastic Oscillator for URGN moved into oversold territory on July 31, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where URGN advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 164 cases where URGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for URGN moved out of overbought territory on July 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on URGN as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for URGN turned negative on July 24, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
URGN broke above its upper Bollinger Band on July 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. URGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.234) is normal, around the industry mean (19.620). P/E Ratio (0.000) is within average values for comparable stocks, (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (13.280) is also within normal values, averaging (420.906).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapies for urological pathologies
Industry Biotechnology